FORA
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Valuation is based on sales and book value as earnings are currently negative.
- Reasonable Price/Sales (2.21)
- Moderate Price/Book (2.23)
- No current P/E due to losses
- No Graham Number available
Growth is strong, but the quality of that growth is questionable.
- Strong YoY and Q/Q revenue growth (~37%)
- Forward P/E of 23.78 implies expected earnings
- Inconsistent earnings surprises
- Failure to scale revenue into operating profit
Historical price action is overwhelmingly negative.
- Recent 1Y recovery (+13.5%)
- Catastrophic 5Y return (-82.8%)
- Consistent failure to maintain price levels
Balance sheet is clean (no debt), but operational health is failing.
- Zero debt
- High current and quick ratios
- Piotroski F-Score of 2/9 is a major red flag
- Negative ROE and ROA
Company is in a growth/survival phase; no capital return to shareholders.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for FORA and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
FORA
Forian Inc.
Primary
|
-82.8% | -35.5% | +13.5% | -7.0% | +2.9% | +1.9% |
|
ATHE
Alterity Therapeutics Limited
Peer
|
-80.8% | -8.5% | +6.3% | -45.8% | +14.5% | +2.9% |
|
ASRT
Assertio Holdings, Inc.
Peer
|
-80.4% | -85.9% | -2.8% | -7.5% | -1.3% | -1.5% |
|
DCGO
DocGo Inc.
Peer
|
-94.3% | -93.1% | -77.6% | -55.1% | -15.2% | -9.4% |
|
BTMD
biote Corp.
Peer
|
-85.2% | -74.7% | -54.1% | -47.5% | -16.8% | +10.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
FORA
Forian Inc.
|
BEARISH | $66.86M | - | -9.6% | -9.5% | $2.14 | |
|
ATHE
Alterity Therapeutics Limited
|
BEARISH | $64.35M | - | -43.2% | -223.3% | $3.55 | Compare |
|
ASRT
Assertio Holdings, Inc.
|
BEARISH | $74.82M | - | -24.5% | -21.1% | $11.66 | Compare |
|
DCGO
DocGo Inc.
|
BEARISH | $56.28M | - | -89.0% | -56.6% | $0.57 | Compare |
|
BTMD
biote Corp.
|
NEUTRAL | $55.53M | 2.01 | -% | 14.1% | $1.49 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-31 | MCGRAIL CAROLINE STRICKLAND | General Counsel | Stock Award | 150,000 | $336,000 |
Past News Coverage
Recent headlines mentioning FORA from our newsroom.